391 related articles for article (PubMed ID: 8786896)
1. [Dendritic cells and immune function in cancer].
Chaux P
Pathol Biol (Paris); 1995 Dec; 43(10):897-903. PubMed ID: 8786896
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation.
Chaux P; Moutet M; Faivre J; Martin F; Martin M
Lab Invest; 1996 May; 74(5):975-83. PubMed ID: 8642792
[TBL] [Abstract][Full Text] [Related]
3. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
4. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression.
Ozawa H; Aiba S; Nakagawa ; Tagami H
Eur J Immunol; 1996 Mar; 26(3):648-52. PubMed ID: 8605933
[TBL] [Abstract][Full Text] [Related]
6. Immunologic mechanisms of antitumor activity.
Foss FM
Semin Oncol; 2002 Jun; 29(3 Suppl 7):5-11. PubMed ID: 12068382
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats.
Chaux P; Favre N; Martin M; Martin F
Int J Cancer; 1997 Aug; 72(4):619-24. PubMed ID: 9259401
[TBL] [Abstract][Full Text] [Related]
8. T-Cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor.
Chaux P; Martin MS; Martin F
Int J Cancer; 1996 Apr; 66(2):244-8. PubMed ID: 8603819
[TBL] [Abstract][Full Text] [Related]
9. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
Front Immunol; 2018; 9():822. PubMed ID: 29755461
[TBL] [Abstract][Full Text] [Related]
10. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
11. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
12. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
13. The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes.
Joncker NT; Bettini S; Boulet D; Guiraud M; Guerder S
Eur J Immunol; 2016 Mar; 46(3):609-18. PubMed ID: 26626316
[TBL] [Abstract][Full Text] [Related]
14. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
15. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
16. Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs.
Kufer P; Zettl F; Borschert K; Lutterbüse R; Kischel R; Riethmüller G
Cancer Immun; 2001 Nov; 1():10. PubMed ID: 12747771
[TBL] [Abstract][Full Text] [Related]
17. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
Mangino G; Grazia Capri M; Barnaba V; Alberti S
Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
[TBL] [Abstract][Full Text] [Related]
18. Langerhans' cells in vernal keratoconjunctivitis express the costimulatory molecule B7-2 (CD86), but not B7-1 (CD80).
Abu-El-Asrar AM; Al-Kharashi SA; Al-Mansouri S; Missotten L; Geboes K
Eye (Lond); 2001 Oct; 15(Pt 5):648-54. PubMed ID: 11702979
[TBL] [Abstract][Full Text] [Related]
19. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens.
Melero I; Bach N; Chen L
Life Sci; 1997; 60(23):2035-41. PubMed ID: 9180357
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified tumour vaccines--where we are today.
Nawrocki S; Mackiewicz A
Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
